CG Oncology (CGON) Free Cash Flow (2023 - 2026)

CG Oncology (CGON) has 4 years of Free Cash Flow data on file, last reported at -$57.2 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 95.28% year-over-year to -$57.2 million; the trailing twelve-month figure through Mar 2026 stood at -$160.4 million (down 95.08% YoY), and the FY2025 full-year result was -$132.5 million, down 67.81% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$57.2 million, down from -$36.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$8.0 million in Q1 2023 and bottomed at -$57.2 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$20.9 million (2024), against an average of -$24.2 million.
• The widest annual swing landed in 2024, when Free Cash Flow sank 225.87%; it then decreased 12.56% in 2025.
• A 4-year view of Free Cash Flow shows it stood at -$14.6 million in 2023, then sank by 42.51% to -$20.9 million in 2024, then sank by 73.7% to -$36.3 million in 2025, then tumbled by 57.79% to -$57.2 million in 2026.
• The last three Free Cash Flow figures came in at -$57.2 million (Q1 2026), -$36.3 million (Q4 2025), and -$39.0 million (Q3 2025), per Business Quant data.

Peer Comparison